Quarterly report pursuant to Section 13 or 15(d)

Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details)

v3.20.2
Note 2 - Summary of Significant Accounting Policies - Antidilutive Securities (Details) - shares
6 Months Ended
Jun. 30, 2020
Jun. 30, 2019
Series B Convertible Preferred Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 22,016,179 [1]
Common Stock Warrants [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 23,583,290 6,408
Share-based Payment Arrangement, Option [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 10,023,441 53,092
Restricted Stock [Member]    
Antidilutive Securities Excluded from Computation of Earnings Per Share (in shares) 2,348 3,916
[1] As of June 30, 2020, a total of 33,685 shares of Series B convertible preferred stock were outstanding and are convertible into 22,016,179 shares of common stock. Each share of Series B preferred stock is convertible at the holder's option into shares of common stock at a conversion ratio of 1-for-653.59 per share determined by dividing the Series B liquidation amount of $1,000 per share by the Series B conversion price of $1.53 per share. However, under the terms of the Series B Preferred Stock and Warrant Purchase Agreement, as amended, CRG will not convert the Series B preferred stock or exercise the CRG warrants until the Company's stockholders act to authorize additional number of shares of common stock sufficient to cover the conversion shares.